The Europe Fusion Biopsy Market is expected to witness market growth of 11.1% CAGR during the forecast period (2020-2026).
Diagnostics centers are anticipated to grow at a substantial rate in the coming years. It reduces wait times, developing reimbursement paradigm, and cost efficiency are some of the factors that are likely to drive the growth of the fusion biopsy market. The targeted MR/Ultrasound biopsy system is an evolving technology, the higher cost is the main barrier for their implementation in diagnostic centers. Though, it is perceived that when two diagnostic centers become partners and purchase and MR/Ultrasound fusion biopsy system, intending its quick ROI and also increasing demand for fusion biopsy.
Transperineal fusion biopsy is an evolving trend and is anticipated to show the fastest growth in the foreseeable period of time. It has a lower risk of infection and minimal rectal bleeding as compared to the traditional approach is likely to have a positive driver towards the segment growth. Furthermore, the transperineal approach is effective and more efficient in assessing the ventral areas of the prostate that are usually not identified with transrectal fusion biopsy. The market players like and Biopsee and Koelis offers accessories of both transrectal and transperineal fusion biopsy system and they are giving urologist more flexibility to facilitate personalized patient care.
Based on End Use, the market is segmented into Diagnostic centers, Hospitals and Ambulatory care centers. Based on Route, the market is segmented into Transperineal and Transrectal. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Koninklijke Philips N.V., Hitachi, Ltd., Baxter International, Inc. (MedCom), Esaote SpA, Eigen, KOELIS, Inc., Focal Healthcare, Inc. and UC-Care Medical Systems Ltd.
Scope of the Study
Market Segmentation:
By End Use
By Route
By Country
Companies Profiled
Unique Offerings from the Publisher
Diagnostics centers are anticipated to grow at a substantial rate in the coming years. It reduces wait times, developing reimbursement paradigm, and cost efficiency are some of the factors that are likely to drive the growth of the fusion biopsy market. The targeted MR/Ultrasound biopsy system is an evolving technology, the higher cost is the main barrier for their implementation in diagnostic centers. Though, it is perceived that when two diagnostic centers become partners and purchase and MR/Ultrasound fusion biopsy system, intending its quick ROI and also increasing demand for fusion biopsy.
Transperineal fusion biopsy is an evolving trend and is anticipated to show the fastest growth in the foreseeable period of time. It has a lower risk of infection and minimal rectal bleeding as compared to the traditional approach is likely to have a positive driver towards the segment growth. Furthermore, the transperineal approach is effective and more efficient in assessing the ventral areas of the prostate that are usually not identified with transrectal fusion biopsy. The market players like and Biopsee and Koelis offers accessories of both transrectal and transperineal fusion biopsy system and they are giving urologist more flexibility to facilitate personalized patient care.
Based on End Use, the market is segmented into Diagnostic centers, Hospitals and Ambulatory care centers. Based on Route, the market is segmented into Transperineal and Transrectal. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Koninklijke Philips N.V., Hitachi, Ltd., Baxter International, Inc. (MedCom), Esaote SpA, Eigen, KOELIS, Inc., Focal Healthcare, Inc. and UC-Care Medical Systems Ltd.
Scope of the Study
Market Segmentation:
By End Use
- Diagnostic centers
- Hospitals
- Ambulatory care centers
By Route
- Transperineal
- Transrectal
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Companies Profiled
- Koninklijke Philips N.V.
- Hitachi, Ltd.
- Baxter International, Inc. (MedCom)
- Esaote SpA
- Eigen
- KOELIS, Inc.
- Focal Healthcare, Inc.
- UC-Care Medical Systems Ltd.
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. Europe Fusion Biopsy Market by End Uses
Chapter 5. Europe Fusion Biopsy Market by Route
Chapter 6. Europe Fusion Biopsy Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Koninklijke Philips N.V.
- Hitachi, Ltd.
- Baxter International, Inc. (MedCom)
- Esaote SpA
- Eigen
- KOELIS, Inc.
- Focal Healthcare, Inc.
- UC-Care Medical Systems Ltd.
Methodology
LOADING...
